Subtopic Deep Dive
Medication-Assisted Treatment for Opioid Use Disorder
Research Guide
What is Medication-Assisted Treatment for Opioid Use Disorder?
Medication-Assisted Treatment (MAT) for Opioid Use Disorder (OUD) combines pharmacotherapies such as methadone, buprenorphine, and naltrexone with behavioral therapies to treat opioid dependence.
MAT reduces overdose deaths and relapse rates compared to nonpharmacologic treatments, as shown in real-world studies (Wakeman et al., 2020, 897 citations). A meta-analysis confirms MAT lowers mortality among opioid users (Ma et al., 2018, 375 citations). Over 10 papers since 2018 examine MAT efficacy, access barriers, and implementation in diverse populations.
Why It Matters
MAT serves as the gold standard for OUD treatment, decreasing overdose mortality by up to 50% in clinical settings (Ma et al., 2018). Real-world data reveal superior outcomes for pathways including medications over psychosocial therapy alone (Wakeman et al., 2020). Access disparities tied to racial segregation limit buprenorphine and methadone availability in underserved counties (Goedel et al., 2020; Haffajee et al., 2019). Policy reforms targeting provider shortages enhance treatment capacity (Haffajee et al., 2018). Youth with timely MAT show higher retention rates than behavioral treatment only (Hadland et al., 2018).
Key Research Challenges
Stigma Hindering MAT Adoption
Stigma blocks effective responses to the opioid crisis, reducing MAT uptake despite proven benefits (Tsai et al., 2019, 391 citations). Providers and patients face barriers from negative perceptions of medications like methadone. Interventions must address cultural attitudes to improve access.
Geographic Access Disparities
Racial/ethnic segregation correlates with lower MAT capacity in US counties (Goedel et al., 2020, 284 citations). High-overdose areas often lack providers for buprenorphine or methadone (Haffajee et al., 2019, 265 citations). Rural and segregated regions show persistent gaps in treatment infrastructure.
Provider Workforce Shortages
Insufficient trained providers limits buprenorphine prescribing due to regulatory hurdles (Haffajee et al., 2018, 241 citations). Policy changes are needed to expand the workforce. Low clinician density exacerbates issues in high-risk counties (Haffajee et al., 2019).
Essential Papers
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Sarah E. Wakeman, Marc R. Larochelle, Omid Ameli et al. · 2020 · JAMA Network Open · 897 citations
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative ef...
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Alexander C. Tsai, Mathew V. Kiang, Michael L. Barnett et al. · 2019 · PLoS Medicine · 391 citations
Alexander Tsai and co-authors discuss the role of stigma in responses to the US opioid crisis.
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis
Jun Ma, Yanping Bao, Rujia Wang et al. · 2018 · Molecular Psychiatry · 375 citations
Medication Treatment of Opioid Use Disorder
James Bell, John Strang · 2019 · Biological Psychiatry · 305 citations
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a f...
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States
William C. Goedel, Aaron Shapiro, Magdalena Cerdá et al. · 2020 · JAMA Network Open · 284 citations
These findings suggest that the racial/ethnic composition of a community was associated with which medications residents would likely be able to access when seeking treatment for opioid use disorde...
Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder
Rebecca L. Haffajee, Lewei Lin, Amy S. B. Bohnert et al. · 2019 · JAMA Network Open · 265 citations
Counties with low availability of OUD medication providers and high rates of opioid overdose mortality were less likely to be micropolitan and have lower primary care clinician density, but were mo...
Polysubstance use in the U.S. opioid crisis
Wilson M. Compton, Rita J. Valentino, Robert L. DuPont · 2020 · Molecular Psychiatry · 261 citations
Reading Guide
Foundational Papers
Start with Bell & Strang (2019) for core pharmacotherapies (methadone, buprenorphine); Ma et al. (2018) for mortality meta-analysis establishing MAT efficacy baselines.
Recent Advances
Wakeman et al. (2020) for real-world pathway comparisons; Goedel et al. (2020) and Haffajee et al. (2019) for access disparities in high-risk areas.
Core Methods
Real-world cohort studies (Wakeman et al., 2020); systematic reviews/meta-analyses (Ma et al., 2018); geospatial analyses of county-level capacity (Goedel et al., 2020).
How PapersFlow Helps You Research Medication-Assisted Treatment for Opioid Use Disorder
Discover & Search
Research Agent uses searchPapers and citationGraph to map MAT literature from Wakeman et al. (2020, 897 citations), revealing pathways with highest impact. exaSearch uncovers access disparity studies like Goedel et al. (2020); findSimilarPapers extends to related segregation effects.
Analyze & Verify
Analysis Agent applies readPaperContent to extract retention metrics from Hadland et al. (2018), then verifyResponse with CoVe checks claims against meta-analyses like Ma et al. (2018). runPythonAnalysis performs GRADE grading on mortality reductions and statistical verification of real-world efficacy from Wakeman et al. (2020).
Synthesize & Write
Synthesis Agent detects gaps in youth MAT access from Hadland et al. (2018) versus adult studies; Writing Agent uses latexEditText, latexSyncCitations for trial reports, and latexCompile for publication-ready reviews with exportMermaid diagrams of treatment pathways.
Use Cases
"Compare retention rates in buprenorphine vs methadone for youth OUD from recent trials"
Research Agent → searchPapers + citationGraph on Hadland et al. (2018) → Analysis Agent → runPythonAnalysis (pandas meta-analysis of retention data) → researcher gets CSV of odds ratios and GRADE-scored evidence table.
"Draft a review on MAT access barriers with citations and pathway diagram"
Research Agent → exaSearch for Haffajee et al. (2019) → Synthesis Agent → gap detection → Writing Agent → latexSyncCitations + latexCompile + exportMermaid (county disparity graph) → researcher gets compiled LaTeX PDF.
"Find code for simulating MAT policy impacts on overdose rates"
Research Agent → paperExtractUrls from Goedel et al. (2020) → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets vetted simulation scripts with agent-based models for access equity.
Automated Workflows
Deep Research workflow conducts systematic reviews of 50+ MAT papers, chaining searchPapers → citationGraph → GRADE grading for structured reports on efficacy (e.g., Wakeman et al., 2020). DeepScan applies 7-step analysis with CoVe checkpoints to verify mortality claims from Ma et al. (2018). Theorizer generates hypotheses on stigma-MAT interactions from Tsai et al. (2019).
Frequently Asked Questions
What is Medication-Assisted Treatment for OUD?
MAT combines FDA-approved medications (methadone, buprenorphine, naltrexone) with counseling to treat opioid dependence (Bell & Strang, 2019).
What are key methods in MAT research?
Clinical trials compare MOUD pathways to nonpharmacologic care; meta-analyses assess mortality (Wakeman et al., 2020; Ma et al., 2018).
What are seminal papers on MAT?
Wakeman et al. (2020, 897 citations) shows real-world superiority of MOUD; Ma et al. (2018, 375 citations) meta-analyzes mortality reductions.
What open problems exist in MAT?
Expanding provider access in segregated counties (Goedel et al., 2020); overcoming stigma (Tsai et al., 2019); youth retention strategies (Hadland et al., 2018).
Research Opioid Use Disorder Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Medication-Assisted Treatment for Opioid Use Disorder with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Opioid Use Disorder Treatment Research Guide